Profile: Aradigm Corp. develops inhalation drug products for patients with severe pulmonary disease. Our respiratory inhalation products are used for the treatment of cystic fibrosis, bronchiectasis, inhalation anthrax and tobacco smoking cessation. ARD-3100 and ARD-3150 - Liposomal Ciprofloxacin are used for the treatment and control of respiratory infections associated with chronic diseases such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis. ARD-1100 is used for the prevention and treatment of pulmonary anthrax infections. This product may potentially be able to deliver a long-acting formulation of ciprofloxacin directly into the lung and could have fewer side effects. Our ARD-1600 - (Nicotine) Tobacco Smoking Cessation Therapy involves developing an inhaled nicotine product that would address effectively the acute craving for cigarettes and, through gradual reduction of the peak nicotine levels, wean-off the patients from cigarette smoking & nicotine addiction. In this therapy, aqueous solutions of nicotine are delivered using the palm-size AERx Essence® system.